Free Trial

D. Boral Capital Reiterates "Buy" Rating for Context Therapeutics (NASDAQ:CNTX)

Context Therapeutics logo with Medical background

Key Points

  • D. Boral Capital has reaffirmed a "Buy" rating for Context Therapeutics (NASDAQ:CNTX) with a target price of $9.00.
  • The stock currently has a consensus rating of "Moderate Buy" with a target price averaging $5.20, while other analysts hold mixed ratings from "Sell" to "Overweight."
  • Context Therapeutics reported a miss on earnings per share, posting ($0.09), compared to analysts' consensus estimates of ($0.06).
  • MarketBeat previews the top five stocks to own by November 1st.

Context Therapeutics (NASDAQ:CNTX - Get Free Report)'s stock had its "buy" rating reaffirmed by stock analysts at D. Boral Capital in a research note issued on Thursday,Benzinga reports. They currently have a $9.00 target price on the stock.

A number of other brokerages have also recently weighed in on CNTX. Weiss Ratings reissued a "sell (d-)" rating on shares of Context Therapeutics in a research note on Wednesday, October 8th. Piper Sandler reissued an "overweight" rating and issued a $4.00 price target (down previously from $4.50) on shares of Context Therapeutics in a research note on Thursday, June 26th. Cantor Fitzgerald began coverage on Context Therapeutics in a research note on Thursday, October 2nd. They issued an "overweight" rating on the stock. Guggenheim began coverage on Context Therapeutics in a research note on Thursday, September 18th. They issued a "buy" rating and a $5.00 price target on the stock. Finally, HC Wainwright dropped their price target on Context Therapeutics from $5.00 to $4.00 and set a "buy" rating on the stock in a research note on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $5.20.

Check Out Our Latest Report on Context Therapeutics

Context Therapeutics Stock Down 2.9%

NASDAQ:CNTX opened at $1.34 on Thursday. The business's 50-day moving average price is $0.93 and its 200 day moving average price is $0.80. The firm has a market cap of $120.20 million, a P/E ratio of -3.72 and a beta of 1.93. Context Therapeutics has a 52-week low of $0.49 and a 52-week high of $2.59.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.03). Sell-side analysts expect that Context Therapeutics will post -0.51 EPS for the current year.

About Context Therapeutics

(Get Free Report)

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.

Featured Articles

Analyst Recommendations for Context Therapeutics (NASDAQ:CNTX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Context Therapeutics Right Now?

Before you consider Context Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Context Therapeutics wasn't on the list.

While Context Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report
Like this article? Share it with a colleague.